Treatment of chronic medical conditions: Cognitive-behavioral therapy strategies and integrative treatment protocols.

Author(s):  
Len Sperry
2015 ◽  
Vol 175 (9) ◽  
pp. 1461 ◽  
Author(s):  
Jade Q. Wu ◽  
Erica R. Appleman ◽  
Robert D. Salazar ◽  
Jason C. Ong

2015 ◽  
Vol 23 (2) ◽  
pp. 93-115 ◽  
Author(s):  
A.I. Melehin ◽  
Yu.V. Veselkova

Over the past few years, cognitive-behavioral therapy, aimed at forecasting and min¬imizing recidivism, was the most effective treatment for substance dependence (opiate addiction, cocainism, kannabizm and polydrug use). This article describes the psychotherapeutic treatment protocols polinarkozavisimosti. Given the short-term integrative principles of cognitive-behavioral therapy, along with motivational thera¬py, psychoeducation and systemic family therapy. Presents the steps of motivational interviewing, functional analysis of problem behavior, social skills training and tech¬niques to overcome the negative stress based on the principle of awareness. Particular attention in this article on the prevention of recurrence in patients with polydrug use.


Author(s):  
Michael L. Sulkowski ◽  
Grai Bluez ◽  
Ariel McKinney ◽  
Jaclyn Wolf

Children with chronic medical conditions often require more mental health supports than their peers without health problems due to increased levels of stress related to the uncertainty of their health, frequent absences from school, and other demands associated with the treatment or management of their illnesses. This chapter provides information about the use and adaptation of cognitive-behavioral therapy (CBT) intervention strategies for children with chronic health conditions in schools. Research supports the efficacy of using CBT in school settings for children displaying varied chronic medical conditions. The chapter reviews the key components of CBT as well as research, scholarship, and clinically relevant information on the use of CBT interventions for pediatric health concerns as they relate to school-age youth. In particular, the following evidence-based CBT components are discussed: psychoeducation, cognitive restructuring, relaxation training and stress management, and behavioral exposure.


Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Nynke L. Rauwerda ◽  
Hans Knoop ◽  
Irene Pot ◽  
Annemieke van Straten ◽  
Marian E. Rikkert ◽  
...  

Abstract Background Insomnia is common in people with long-term medical conditions and is related to increased mortality and morbidity. Cognitive behavioral therapy for insomnia (CBT-I) is first choice treatment and effective for people with insomnia and comorbid long-term medical conditions. However, CBT-I has some limitations as it might not always be available or appeal to patients with medical conditions. Furthermore, a small proportion of patients do not respond to CBT-I. Preliminary evidence and clinical experience suggest that low-dose amitriptyline (AM) might be an effective alternative to treat insomnia in patients with medical comorbidity. In this randomized controlled trial, we will determine whether AM is non-inferior to the first choice treatment for insomnia, CBT-I. Methods/design This study will test if treatment with low-dose amitriptyline for insomnia in patients with medical comorbidity is non-inferior to CBT-I in a multicenter randomized controlled non-inferiority trial. Participants will be 190 adults with a long-term medical condition and insomnia. Participants will be randomly allocated to one of two intervention arms: 12 weeks AM (starting with 10 mg per day, and if ineffective at 3 weeks, doubling this dose) or 12 weeks of CBT-I consisting of 6 weekly sessions and a follow-up session 6 weeks later. The primary outcome is subjective insomnia severity, measured with the Insomnia Severity Index (ISI). The primary endpoint is at 12 weeks. Secondary outcomes include sleep quality (e.g., sleep efficiency), questionnaires on daytime functioning (physical functioning and impairment of functioning), and symptoms (e.g., fatigue, pain, anxiety) at 12 weeks and 12 months post treatment and relapse of insomnia until 12 months after treatment. Discussion Irrespective of the outcome, this study will be a much-needed contribution to evidence based clinical guidelines on the treatment of insomnia in patients with medical comorbidity. Trial registration Dutch Trial Register NTR NL7971. Registered on 18 August 2019


2018 ◽  
Vol 19 ◽  
pp. 868-875 ◽  
Author(s):  
Katherine E. MacDuffie ◽  
Jeff MacInnes ◽  
Kathryn C. Dickerson ◽  
Kari M. Eddington ◽  
Timothy J. Strauman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document